血液腫瘍検査市場- 世界の産業規模、シェア、動向、機会、予測、がんタイプ別、製品タイプ別、技術地域別、競合市場別、2020-2030F

血液腫瘍検査の世界市場規模は、2024年に31億4,000万米ドルとなり、予測期間中のCAGRは8.91%で、2030年には52億4,000万米ドルに達すると予測されます。

世界の血液腫瘍検査市場は、ヘルスケア診断の広範な分野の中でダイナミックかつ急速に発展している分野です。この市場には主に、白血病、リンパ腫、骨髄腫など、血液や骨髄に影響を及ぼす血液悪性腫瘍やがんの診断とモニタリングを目的とした幅広い診断検査や処置が含まれます。血液腫瘍検査に対する需要は、血液関連がんの発生率の増加、診断技術の進歩、がんの早期発見に対する意識の高まりにより、近年急増しています。

同市場の成長促進要因のひとつは、世界のがん罹患率の上昇です。血液悪性腫瘍はがん患者のかなりの部分を占めており、効果的な治療計画を立てるためには正確で早期診断が必要です。このため、次世代シーケンシング、フローサイトメトリー、PCRベースのアッセイなど、血液細胞内のがん変異や異常をより包括的かつ正確に評価できる革新的な検査法の開発が促進されています。

主な市場促進要因

血液悪性腫瘍の発生率の上昇

主な市場課題

高度な検査費用の高騰

主要市場動向

ゲノムプロファイリングの進歩

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の血液腫瘍検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • がんの種類別（白血病、リンパ腫、骨髄増殖性腫瘍、その他のがん）
  • 製品別（アッセイキットおよび試薬、サービス）
  • 技術別（PCR、IHC、NGS、細胞遺伝学、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • がんの種類別
  • 製品別
  • 技術別
  • 地域別

第5章 アジア太平洋地域の血液腫瘍検査市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • がんの種類別
  • 製品別
  • 技術別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の血液腫瘍検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の血液腫瘍検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の血液腫瘍検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの血液腫瘍検査市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の血液腫瘍検査市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• F. Hoffmann-La Roche Ltd
• EntroGen, Inc.
• Qiagen N.V.
• Abbott Laboratories Inc.
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Illumina, Inc.
• Amoy Diagnostics Co. Ltd.
• ASURAGEN, INC
• ArcherDX, Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Hemato Oncology Testing Market was valued at USD 3.14 billion in 2024 and is expected to reach USD 5.24 billion by 2030 with a CAGR of 8.91% during the forecast period. The Global Hemato-Oncology Testing Market is a dynamic and rapidly evolving sector within the broader field of healthcare diagnostics. This market primarily encompasses a wide array of diagnostic tests and procedures aimed at diagnosing and monitoring hematological malignancies and cancers affecting the blood and bone marrow, such as leukemia, lymphoma, and myeloma. The demand for hemato-oncology testing has surged in recent years due to the increasing incidence of blood-related cancers, advancements in diagnostic technologies, and the growing awareness of early cancer detection.

One of the key drivers for the growth of this market is the rising global cancer burden. Hematological malignancies represent a significant portion of cancer cases, necessitating precise and early diagnosis for effective treatment planning. This has fueled the development of innovative testing methods, including next-generation sequencing, flow cytometry, and PCR-based assays, which allow for a more comprehensive and precise assessment of cancerous mutations and abnormalities in blood cells.

Key Market Drivers

Rising Incidence of Hematological Malignancies

The rising incidence of hematological malignancies is a pivotal driver behind the burgeoning growth of the global hemato-oncology testing market. Hematological malignancies, encompassing conditions like leukemia, lymphoma, and myeloma, have seen a significant and concerning increase in diagnoses worldwide. Several factors contribute to this alarming trend, including changes in demographics, environmental factors, and lifestyle choices.

One primary contributor to the rising incidence of hematological malignancies is the aging population. As people live longer, their risk of developing these blood-related cancers increases, particularly after the age of 60. The aging demographic across the globe has led to an uptick in cancer cases, necessitating a surge in diagnostic testing to identify and address these malignancies at an early stage.

Environmental factors and exposure to carcinogens have also played a role in the increased incidence of these cancers. Pesticides, radiation exposure, industrial chemicals, and certain viral infections have been linked to the development of hematological malignancies. As these risk factors persist in various regions, individuals face a heightened likelihood of developing these cancers, prompting the need for robust testing to enable early detection and intervention.

Furthermore, lifestyle choices and habits have contributed to the rising prevalence of hematological malignancies. Smoking, excessive alcohol consumption, and unhealthy dietary patterns have been associated with an increased risk of blood-related cancers. The global adoption of these risk factors, in conjunction with sedentary lifestyles and obesity, has added to the burden of these malignancies. Early diagnosis through hemato-oncology testing is critical to stemming the impact of these lifestyle-related risks on cancer development.

Key Market Challenges

High Cost of Advanced Testing

The Global Hemato-Oncology Testing Market has made significant strides in improving cancer diagnosis and treatment. However, a prominent roadblock to its expansion is the high cost associated with advanced testing methods. Hemato-oncology testing, which involves the diagnosis and monitoring of blood-related cancers like leukemia, lymphoma, and myeloma, relies heavily on sophisticated technologies that come with a steep price tag.

Advanced diagnostic techniques, such as next-generation sequencing (NGS), flow cytometry, and polymerase chain reaction (PCR) assays, have revolutionized the field of hemato-oncology. They offer higher sensitivity, greater accuracy, and a deeper understanding of cancer at the genetic and molecular level. These technologies have the potential to make a substantial difference in patient care, including personalized treatment plans and early detection.

However, the substantial cost of implementing and sustaining these technologies presents a formidable challenge. The expenses include the purchase of specialized equipment, maintenance, personnel training, and data analysis. All these factors contribute to the overall high cost of hemato-oncology testing, making it inaccessible to many patients and healthcare providers.

Key Market Trends

Advancements in Genomic Profiling

Advancements in genomic profiling have emerged as a pivotal driving force behind the remarkable growth of the Global Hemato-Oncology Testing Market. Hematological malignancies, a diverse group of cancers affecting the blood and bone marrow, have seen a transformative evolution thanks to the utilization of cutting-edge genomic profiling techniques.

One of the most noteworthy trends within the hemato-oncology testing market is the widespread adoption of genomic profiling methods, prominently including next-generation sequencing (NGS). These technologies offer the ability to delve deeper into the genetic and molecular alterations of blood cells, providing a more comprehensive understanding of hematological malignancies. This depth of information is invaluable for clinicians in diagnosing these complex cancers and tailoring treatment strategies to individual patients.

NGS, in particular, stands out as a game-changer in hemato-oncology testing. It can analyze large volumes of genetic information with unprecedented speed and precision. This enables healthcare professionals to identify specific mutations, genetic abnormalities, and biomarkers that are characteristic of hematological malignancies. With this knowledge, clinicians can make more informed decisions regarding treatment selection and prognosis, ultimately improving patient outcomes and the quality of care.

Key Market Players

• F. Hoffmann-La Roche Ltd
• EntroGen, Inc.
• Qiagen N.V.
• Abbott Laboratories Inc.
• Thermo Fisher Scientific, Inc.
• Bio-Rad Laboratories, Inc.
• Illumina, Inc.
• Amoy Diagnostics Co. Ltd.
• ASURAGEN, INC
• ArcherDX, Inc

Report Scope:

In this report, the Global Hemato Oncology Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hemato Oncology Testing Market, By Cancer Type:

• Leukemia
• Lymphoma
• Myeloproliferative Neoplasms
• Other Cancers

Hemato Oncology Testing Market, By Product:

• Assay Kits and Reagents
• Services

Hemato Oncology Testing Market, By Technology:

• PCR
• IHC
• NGS
• Cytogenetics
• Other

Hemato Oncology Testing Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hemato Oncology Testing Market.

Available Customizations:

Global Hemato Oncology Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Hemato Oncology Testing Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Cancer Type (Leukemia, Lymphoma, Myeloproliferative Neoplasms, Other Cancers)
  • 4.2.2. By Product (Assay Kits and Reagents, Services)
  • 4.2.3. By Technology (PCR, IHC, NGS, Cytogenetics, Other )
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Cancer Type
  • 4.3.2. By Product
  • 4.3.3. By Technology
  • 4.3.4. By Region

5. Asia Pacific Hemato Oncology Testing Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Cancer Type
  • 5.2.2. By Product
  • 5.2.3. By Technology
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Hemato Oncology Testing Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Cancer Type
      • 5.3.1.2.2. By Product
      • 5.3.1.2.3. By Technology
  • 5.3.2. India Hemato Oncology Testing Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Cancer Type
      • 5.3.2.2.2. By Product
      • 5.3.2.2.3. By Technology
  • 5.3.3. Australia Hemato Oncology Testing Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Cancer Type
      • 5.3.3.2.2. By Product
      • 5.3.3.2.3. By Technology
  • 5.3.4. Japan Hemato Oncology Testing Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Cancer Type
      • 5.3.4.2.2. By Product
      • 5.3.4.2.3. By Technology
  • 5.3.5. South Korea Hemato Oncology Testing Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Cancer Type
      • 5.3.5.2.2. By Product
      • 5.3.5.2.3. By Technology

6. Europe Hemato Oncology Testing Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Cancer Type
  • 6.2.2. By Product
  • 6.2.3. By Technology
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Hemato Oncology Testing Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Cancer Type
      • 6.3.1.2.2. By Product
      • 6.3.1.2.3. By Technology
  • 6.3.2. Germany Hemato Oncology Testing Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Cancer Type
      • 6.3.2.2.2. By Product
      • 6.3.2.2.3. By Technology
  • 6.3.3. Spain Hemato Oncology Testing Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Cancer Type
      • 6.3.3.2.2. By Product
      • 6.3.3.2.3. By Technology
  • 6.3.4. Italy Hemato Oncology Testing Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Cancer Type
      • 6.3.4.2.2. By Product
      • 6.3.4.2.3. By Technology
  • 6.3.5. United Kingdom Hemato Oncology Testing Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Cancer Type
      • 6.3.5.2.2. By Product
      • 6.3.5.2.3. By Technology

7. North America Hemato Oncology Testing Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Cancer Type
  • 7.2.2. By Product
  • 7.2.3. By Technology
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Hemato Oncology Testing Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Cancer Type
      • 7.3.1.2.2. By Product
      • 7.3.1.2.3. By Technology
  • 7.3.2. Mexico Hemato Oncology Testing Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Cancer Type
      • 7.3.2.2.2. By Product
      • 7.3.2.2.3. By Technology
  • 7.3.3. Canada Hemato Oncology Testing Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Cancer Type
      • 7.3.3.2.2. By Product
      • 7.3.3.2.3. By Technology

8. South America Hemato Oncology Testing Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Cancer Type
  • 8.2.2. By Product
  • 8.2.3. By Technology
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Hemato Oncology Testing Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Cancer Type
      • 8.3.1.2.2. By Product
      • 8.3.1.2.3. By Technology
  • 8.3.2. Argentina Hemato Oncology Testing Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Cancer Type
      • 8.3.2.2.2. By Product
      • 8.3.2.2.3. By Technology
  • 8.3.3. Colombia Hemato Oncology Testing Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Cancer Type
      • 8.3.3.2.2. By Product
      • 8.3.3.2.3. By Technology

9. Middle East and Africa Hemato Oncology Testing Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Cancer Type
  • 9.2.2. By Product
  • 9.2.3. By Technology
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Hemato Oncology Testing Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Cancer Type
      • 9.3.1.2.2. By Product
      • 9.3.1.2.3. By Technology
  • 9.3.2. Saudi Arabia Hemato Oncology Testing Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Cancer Type
      • 9.3.2.2.2. By Product
      • 9.3.2.2.3. By Technology
  • 9.3.3. UAE Hemato Oncology Testing Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Cancer Type
      • 9.3.3.2.2. By Product
      • 9.3.3.2.3. By Technology

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Hemato Oncology Testing Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. F. Hoffmann-La Roche Ltd
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. Key Personnel Details
  • 14.1.7. SWOT Analysis
• 14.2. EntroGen, Inc.
• 14.3. Qiagen N.V.
• 14.4. Abbott Laboratories Inc.
• 14.5. Thermo Fisher Scientific, Inc.
• 14.6. Bio-Rad Laboratories, Inc.
• 14.7. Illumina, Inc.
• 14.8. Amoy Diagnostics Co. Ltd.
• 14.9. ASURAGEN, INC
• 14.10. ArcherDX, Inc.

15. Strategic Recommendations

16. About Us & Disclaimer